Microsoft word - pipeline table - feb1 14.18hrs.docx
Development Pipeline as at 31 December 2011
Line Extensions
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Cardiovascular
add-on to metformin LT data diabetes – in patients with
Gastrointestinal
#Partnered product *Kombiglyze XRTM US; KomboglyzeTM FDC EU **2nd CRL received in June 2011
Line Extensions (continued)
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Infection Neuroscience Oncology Respiratory & Inflammation NCEs Phase III/Registration
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Cardiovascular Infection
virus vaccine (quadrivalent) extended spectrum cephalosporin
Neuroscience Oncology Respiratory & Inflammation
#Partnered product *CRL received in January 2012 **Phase 3 dosing expected in 1Q 2012 ***sBLA in US, MAA in EU ****Enrolment began in 1Q 2011
NCEs Phases I and II
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Cardiovascular Gastrointestinal tralokinumab Infection Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Neuroscience NCEs Phases I and II (continued)
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Oncology
#Partnered product *Added to pipeline table after starting Phase 2 in January 2012
NCEs Phases I and II (continued)
Compound Mechanism Area Under Estimated Filing Investigation Commenced Emerging Respiratory & Inflammation Development Pipeline - Discontinued Projects between 27 January 2011 and 31 December 2011 Cardiovascular NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation
Neuroscience NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation
sedative/anaesthetic cognitive disorders in
Oncology NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation
Infection NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation
Respiratory & Inflammation NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation
Comments As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time. Submission dates shown for assets in Phase III and beyond.
Update on Daubert: What Has It Done to Affect the Right to Jury Trial? Since 1993, when the Supreme Court issued its decision in Daubert v. Merrell Dow Pharmaceuticals, Inc. 1 federal courts have been grappling with how to properly apply the Court’s gatekeeping mandate. Now that many states have adopted Daubert as well, the affect of the Court’s decision has expanded to virtually ev